Hetero announced this week the launch in India of its adalimumab biosimilar, marketed under the brand name Mabura. Mabura is a biosimilar of Abbvie’s Humira and is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders. According to the company, Mabura is Hetero’s fourth biosimilar product.
Glenmark also announced this week that it has entered into a licensing agreement with Zydus Cadila, allowing for Glenmark to market an adalimumab biosimilar under the name Adaly. Zydus will manufacture Adaly, and Glenmark will market it for the treatment of plaque psoriasis and rheumatoid arthritis.
Mabura and Adaly will join other adalimumab biosimilars marketed in India, including Zydus Cadila’s Exemptia, Reliance Life Sciences’ AdaliRel, and Torrent Pharmaceuticals’ Adfrar.
The post Hetero and Glenmark Launch Adalimumab Biosimilars in India appeared first on Goodwin Procter BioSimilars Blog.